Corcept Therapeutics Incorporated (CORT) Company Bio
Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.
CORT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Corcept Therapeutics Inc. To summarize, we found that Corcept Therapeutics Inc ranked in the 95th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for CORT, they are:
The company's balance sheet shows it gets 100% of its capital from equity, and 0% of its capital from debt. Its equity weight surpasses that of 95.31% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.31% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Corcept Therapeutics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -26.74. This coverage rate is greater than that of merely 4.54% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Corcept Therapeutics Inc? See BEAT, USNU, AMRX, ACHC, and AMEH.
Corcept Therapeutics ([[CORT]] -0.2%) has completed enrollment of 177 metastatic ovarian cancer patients in a Phase 2 clinical trial assessing the combination of relacorilant and Bristol Myers Squibb's Abraxane (nab-paclitaxel) in patients who have failed to respond to platinum-based chemo.The primary endpoint is progression-free survival ((PFS)) at month 12. The...
MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the completion of enrollment in its controlled, Phase 2 trial of relacorilant combined with nab-paclitaxel (Abraxane®) in patients with metastatic, platinum-resistant ovarian cancer. “We achieved this milestone thanks in part to the hard work and enthusiasm of our clinical investigators,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. “Data from our open-label, Phase 1/2 trial were very promising.1 We expect to have results from this larger, controlled trial in the first half of ne...